CORLANOR

LOE Approaching

ivabradine

NDAORALSOLUTIONPriority Review
Approved
Apr 2019
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
7

Mechanism of Action

hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has…

Clinical Trials (5)

NCT03619187Phase 3Withdrawn

An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients

Started Nov 2018
0
Heart Transplantation, Elevated Resting Heart Rate
NCT03168529Phase 4Terminated

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

Started Jul 2018
19 enrolled
Heart Failure
NCT03387605Phase 4Unknown

Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

Started Mar 2018
40 enrolled
Heart FailureCardiogenic ShockTachycardia
NCT03137537Phase 2Terminated

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

Started Feb 2018
23 enrolled
LymphomaAutonomic ImbalanceCancer Survivorship
NCT03182725Phase 3Completed

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

Started Feb 2018
37 enrolled
Postural Orthostatic Tachycardia Syndrome

Loss of Exclusivity

LOE Date
Dec 12, 2026
9 months away
Patent Expiry
Dec 12, 2026
Exclusivity Expiry
Oct 22, 2026

Patent Records (4)

Patent #ExpiryTypeUse Code
7361649
Feb 22, 2026Expired
SubstanceProduct
U-1694
7361650
Feb 22, 2026Expired
SubstanceProduct
U-1694
7879842
Feb 22, 2026Expired
SubstanceProduct
U-1694
7867996
Dec 12, 2026
SubstanceProduct
U-1694